What We're Reading: Page 116
Industry reads hand-picked by our editors
Aug 01, 2022
-
The Washington Post
‘Not enough shots’: U.S. faces ‘vaccine cliff’ on monkeypox
-
The Wall Street Journal
Amgen Fights IRS Over $10.7 Billion Tax Bill
-
NPR
Alzheimer’s researchers are looking beyond plaques and tangles for new treatments
-
Fierce Biotech
FDA’s Califf backs limited use of single-arm trials, but says regulatory pathways for some cancers should ‘move into a new phase’
Jul 29, 2022
-
The New York Times
Biden Administration Plans to Offer Updated Booster Shots in September
-
BioCentury
Califf warns of dangers of user fee brinkmanship
-
The Boston Globe
This billionaire has quietly driven Boston’s biotech industry for decades
Jul 28, 2022
Jul 27, 2022
-
Business Insider
Kids with 'bubble boy' disease are dying — even though drug companies have found a cure
-
The Washington Post
Biden administration estimates U.S. may need nearly $7 billion for monkeypox
-
Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement
-
Reuters
Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say
Jul 26, 2022
Jul 25, 2022
-
Forbes
Gingko Buys Embattled Biotech Firm Zymergen For Paltry $300 Million
-
Endpoints News
Turnover tsunami at FDA’s pharma inspections office puts the backlog in sharp focus
-
FT
Slow patient uptake of Pfizer’s Covid drug hints at end to sales boom
-
Nature Biotechnology
RNA drugs lower lipoprotein(a) and genetically driven cholesterol
Jul 22, 2022
-
Science
Potential fabrication in research images threatens key theory of Alzheimer’s disease
-
STAT
Evusheld protects the vulnerable from Covid. Why are so few using it?
-
Kaiser Health News
Parents Become Drug Developers to Save Their Children’s Lives
-
Endpoints News
OrbiMed-backed Silverback, three months after hacking the pipeline, reverse-merges with small allergy biotech
Previous
